State Street
ZBIO

State Street’s Zenas BioPharma ZBIO Stock Holding History

State Street’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.8M Buy
1,470,923
+1,032,629
+236% +$23.2M ﹤0.01% 2042
2025
Q4 		$15.9M Buy
438,294
+60,809
+16% +$2M ﹤0.01% 2382
2025
Q3 		$8.38M Buy
377,485
+67,249
+22% +$1.09M ﹤0.01% 2731
2025
Q2 		$3.01M Buy
310,236
+44,036
+17% +$429K ﹤0.01% 3168
2025
Q1 		$2.1M Buy
266,200
+54,694
+26% +$428K ﹤0.01% 3227
2024
Q4 		$1.73M Buy
+211,506
New +$3.3M ﹤0.01% 3362

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

State Street's ZBIO Position: Q1 2026 in Review

State Street increased its Zenas BioPharma (ZBIO) stake by 236% in Q1 2026, buying an estimated $23.2M and bringing the position to 1,470,923 shares worth $28.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

State Street first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • State Street held 1,470,923 shares of Zenas BioPharma worth $28.8M as of Q1 2026.
  • State Street bought 1,032,629 Zenas BioPharma shares in Q1 2026, an estimated $23.2M.
  • Zenas BioPharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2042 holding.
  • State Street first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.